. . . .This is bad. If you work for Merial, a well run company, this is not good news. If you worked for the old Intervet, it also was well run, this is good news bad news. Good in that the saga of who do I work for is nearing an end. Bad in that they have now seen Raul's management. If you worked for legacy Schering this is of course bad news as you were hoping for new and better management. Raul is of course a chip off the Hassan block. If you work for Merck, you might be glad to be rid of another ex Schering executive team member.
July 28, 2010 7:54 AM. . . .
I trust this is a shared perception among the old Organon/Intervet crowd. Any additional readers willing to weigh in? I will protect your anonymity.